Can-Fite Biopharma Ltd ADR (CANF)
NYSE: CANFHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CANF stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.06M
- EPS (TTM)
- -$13.23
- Dividend yield
- None
- 52-week range
- 1.96 – 12.40
- Day range
- 1.96 – 2.10
- Volume / Avg
- 68.19K / 388.00K
- Beta
- —
- Shares outstanding
- 3.03M
52-week range
CANF stock today
Can-Fite Biopharma (CANF) closed at $2.00 on Oct 8, down 4.76% (-$0.10), versus the S&P 500's 0.47% decline. Trading was light, with 68.19K shares changing hands, about 18% of the average daily volume. At this level, CANF sits near the bottom of its 52-week range of $1.96 to $12.40: 83.9% below the high, set on Nov 18, 2025 and 2.0% above the low.
CANF is down 50.0% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 83.1%. Can-Fite Biopharma has posted a net loss over the last twelve months (EPS of -$13.23), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Can-Fite Biopharma
Company profileCan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Motti Farbstein
- Headquarters
- Ramat Gan
- Employees
- 5
- Website
- canfite.com
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$8.00+300.00%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Can-Fite Biopharma peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMNNImunon Inc. | 1.07 | -4.46% | $6.00M | vs CANF |
| EVGNEvogene Ltd | 0.3985 | -2.95% | $6.30M | vs CANF |
| KALAKALA BIO Inc. | 0.2966 | -17.61% | $5.74M | vs CANF |
| ALZNAlzamend Neuro Inc. | 1.34 | -2.19% | $6.47M | vs CANF |
| CELZCreative Medical Technology Holdings Inc. | 0.8604 | -2.45% | $6.53M | vs CANF |
| XCURExicure Inc. | 1.00 | -1.96% | $6.55M | vs CANF |
| PULMPulmatrix Inc. | 1.53 | +2.49% | $5.58M | vs CANF |
| ADXNAddex Therapeutics Ltd ADR | 3.18 | +6.81% | $5.57M | vs CANF |
Indexes, lists and sector
Appears in lists
Can-Fite Biopharma stock FAQ
What is Can-Fite Biopharma's stock price today?
CANF last traded at $2.00 as of Oct 8, 4:00 PM EDT, down 4.76% on the day. Prices are delayed at least 15 minutes.
Does Can-Fite Biopharma pay a dividend?
No. Can-Fite Biopharma does not currently pay a regular cash dividend.
Who is Can-Fite Biopharma's CEO?
Mr. Motti Farbstein is the chief executive officer of Can-Fite Biopharma Ltd ADR, which has about 5 employees.
Has CANF ever split its stock?
Yes. The most recent CANF stock split was a 1-for-20 split on Jan 5, 2026, one of 3 splits on record.
What is the CANF 52-week high?
The 52-week high for CANF is $12.40 and the 52-week low is $1.96. The stock is currently 83.9% below its high.